XCE Tirzepatide LY3298176 99% Purity GLP-1/GIP Receptor Agonist for Research Use

XCE Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. This compound demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.

The XCE Tirzepatide formulation shows greater affinity for GIP receptors while maintaining significant activity at GLP-1 receptors. This unique dual mechanism has been shown to produce enhanced reductions in hyperglycemia in research models. The compound mimics the actions of natural GIP at the GIP receptor while providing sustained GLP-1 activity.

For research purposes, our XCE Tirzepatide is supplied as high purity white powder with molecular weight 4813.45. The product undergoes strict quality control including HPLC analysis to ensure consistent performance in laboratory studies.

As a dual incretin receptor agonist, XCE Tirzepatide represents an important research tool for investigating metabolic regulation pathways. The compound's ability to simultaneously target both GIP and GLP-1 receptors makes it particularly valuable for diabetes and obesity-related research applications.